Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Abstract Background Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are associated with poor clinical response to PD1/PD-L1...

Full description

Bibliographic Details
Main Authors: Jinyu Zhang, Pablo Saenz-lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, Jennifer D. Wu
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
NKG2D
Soluble MHC I chain related molecule (sMIC)
Cancer
PD1 blockade
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0693-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0693-y

Similar Items